Pfizer Files 8K - Other Events

By Dow Jones Business News, 
A A A


Pfizer Inc. ( PFE ) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on May 15, 2014.

On May 15, 2014, Pfizer Inc. (the "Company") completed a public offering of $4,500,000,000 aggregate principal amount of notes consisting of $500,000,000 aggregate principal amount of Floating Rate Notes due 2017, $1,000,000,000 aggregate principal amount of 1.100% Notes due 2017, $1,500,000,000 aggregate principal amount of 2.100% Notes due 2019, $ 1,000,000,000 aggregate principal amount of 3.400% Notes due 2024 and $500,000,000 aggregate principal amount of 4.400% Notes due 2044 (together, the "Notes").

The offering of the Notes was made pursuant to the Company's shelf registration statement on Form S-3 (Registration No. 333-181321) filed with the Securities and Exchange Commission on May 10, 2012.

In connection with the offering of the Notes, the Company entered into an underwriting agreement and related pricing agreement, each dated May 12, 2014, with Merrill, Lynch, Pierce, Fenner & Smith Incorporated, Barclays Capital Inc., Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein.

The Notes were issued pursuant to an indenture, dated as of January 30, 2001, between the Company and The Bank of New York Mellon (formerly known as The Bank of New York), as successor to JPMorgan Chase Bank (formerly known as The Chase Manhattan Bank), as trustee, as supplemented by the Fourth Supplemental Indenture, dated as of May 15, 2014, between the Company and The Bank of New York Mellon, as trustee.

The underwriting agreement, pricing agreement, indenture, fourth supplemental indenture (including forms of the Notes) and press release related to the offering are filed as exhibits to this Form 8-K and are incorporated herein by reference.

In addition, in connection with the offering of the Notes, the Company is filing a legal opinion regarding the validity of the Notes, attached as Exhibit 5.1 to this Form 8-K.

The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/78003/000119312514201187/ d727538d8k.htm

Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/ 78003/000119312514201187/0001193125-14-201187-index.htm

Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.

Access Investor Kit for Pfizer Inc.

Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=US7170811035

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


  (END) Dow Jones Newswires
  05-15-141629ET
  Copyright (c) 2014 Dow Jones & Company, Inc.


This article appears in: News Headlines

Referenced Stocks: BK , PFE

Dow Jones Business News


More from Dow Jones Business News:

Related Videos

Stocks

Referenced

100%
92%

Most Active by Volume

109,634,263
  • $6.80 ▲ 14.48%
104,983,438
  • $11.83 ▲ 12.35%
95,065,355
  • $3.40 ▲ 0.59%
78,480,140
  • $36.59 ▲ 2.64%
48,726,101
  • $39.91 ▲ 5.83%
45,271,598
  • $15.36 ▼ 0.90%
43,387,835
  • $6.56 ▼ 1.94%
42,066,487
  • $98.38 ▼ 0.65%
As of 7/29/2014, 04:02 PM